ArticleRespiratory medicine case reports2025
DIPNECH: The neuroendocrine enigma behind persistent respiratory symptoms in the post-COVID era.
Article in Respiratory medicine case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) is an underrecognized lung disease that hides in plain sight, often misdiagnosed as asthma or COPD. Its early symptoms such as chronic cough, wheezing, and dyspnea are deceptively nonspecific, leading to diagnostic delays even in patients with classic risk factors like middle-aged, non-smoking females. In one illustrative case, a woman developed unexplained respiratory symptoms following COVID-19, eventually leading to a diagnosis of DIPNECH after incidental imaging revealed pulmonary nodules. The hallmark feature is airway-centered neuroendocrine cell proliferation, which can exist with or without tumorlets or progression to carcinoid tumors. Though symptoms may respond to bronchodilators or corticosteroids, unchecked progression may result in irreversible airflow obstruction. Recognizing DIPNECH early is crucial for timely intervention. When common diagnoses do not fully explain the clinical picture, DIPNECH deserves a place on the differential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.